Press Releases :: Nighthawk Biosciences, Inc. (SCPX)

Mar 14, 2018 7:00am EDT

Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

Mar 13, 2018 7:00am EDT

Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam

Mar 12, 2018 7:00am EDT

Heat Biologics Adopts Stockholder Rights Plan

Mar 02, 2018 4:00pm EST

Heat Biologics Reports Fiscal Year 2017 Financial Results

Feb 28, 2018 6:00am EST

Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Feb 26, 2018 7:00am EST

UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study

Feb 20, 2018 1:00pm EST

Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer

Feb 14, 2018 7:00am EST

Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond

Feb 07, 2018 7:05am EST

Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York

Jan 30, 2018 7:00am EST

Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study

rss_feed News RSS